MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $8.164 million which beat the analyst consensus estimate of $7.374 million by 10.71 percent. This is a 1.99 percent increase over sales of $8.005 million the same period last year.